TY - JOUR
T1 - What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report
AU - Bertagnolli, Monica M.
AU - Blanke, Charles D.
AU - Curran, Walter J.
AU - Hawkins, Douglas S.
AU - Mannel, Robert S.
AU - O’Dwyer, Peter J.
AU - Schnall, Mitchell D.
AU - Wolmark, Norman
N1 - Funding Information:
Monica M. Bertagnolli reports research funding to the Alliance for Clinical Trials in Oncology from AbbVie, Agenus, Astellas, AstraZeneca, Baxalta, Bayer HealthCare, the Breast Cancer Research Foundation, Bristol‐Myers Squib, Celgene, the Chinese Medical Education Association, Complion, Czarnowski, Derse, Inc, Eisai, Exelixis, Genentech, GHI, Gilead Sciences, GSK Total, Incyte Corporation, Janssen, Jazz Pharma, Leap Therapeutics, Leidos, Lexicon Pharma, Lilly, Maltrex, Merck, MITRE Corporation, Millennium, Novartis, Pfizer, Pharmacyclics, the Robert Wood Johnson Foundation, Roche/Genentech, Sagerock Advisors, Sanofi, Servier Affaires Medicales, STO, Syntalogic, Taiho Oncology, Takeda, Tesaro, and Teva, outside the submitted work. Charles D. Blanke reports grants from the National Institutes of Health, during the conduct of the study. Douglas S. Hawkins reports grants from Merck Sharpe & Dohme, Lilly, Eisai, Glaxo Smith Kline, Novartis, Sanofi, Amgen, Seattle Genetics, Jazz Pharmaceuticals, and Incyte; grants and personal fees from Bristol Myers Squibb; and personal fees from AstraZeneca and Celgene, all outside the submitted work. Robert S. Mannel reports personal fees from Tesaro, outside the submitted work. Peter J. O'Dwyer reports research funding from Pfizer, Bristol Myers Squibb, Cooperative Groups, Five Prime, FortySeven, BBI, Novartis, Celgene, Incyte, Lilly/Imclone, h3Biomedicine, Taiho, and Pharmacyclics/AbbVie; grants and personal fees from Genentech and Array; and fees for expert testimony from Bayer and Lilly, all outside the submitted work. Norman Wolmark reports grants from the National Institutes of Health, during the conduct of the study. Mitchel D. Schnall reports grants from Siemens Healthineers outside the submitted work. Walter J. Curran made no disclosures.
Publisher Copyright:
© 2020 American Cancer Society
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The US cancer cooperative groups (cooperative groups) were founded in the 1950s to establish a standing infrastructure to conduct multi-institutional cancer clinical trials. Initially funded almost entirely by the US National Cancer Institute (NCI), over the years, the research conducted by the Cooperative Groups has evolved to meet the demands of cancer clinical research, with a scope now encompassing trials to advance cancer treatment, cancer control, biomarker development and validation, and health services research, with a corresponding broadening of their funding sources. The cooperative groups are also a critical mechanism for educating the next generation of cancer clinical trialists from many different disciplines. This review outlines the overall mission, structure, and funding of the cooperative groups, beginning in 1955 when they were first established by the NCI, and describes the considerable progress against cancer achieved over the past decade.
AB - The US cancer cooperative groups (cooperative groups) were founded in the 1950s to establish a standing infrastructure to conduct multi-institutional cancer clinical trials. Initially funded almost entirely by the US National Cancer Institute (NCI), over the years, the research conducted by the Cooperative Groups has evolved to meet the demands of cancer clinical research, with a scope now encompassing trials to advance cancer treatment, cancer control, biomarker development and validation, and health services research, with a corresponding broadening of their funding sources. The cooperative groups are also a critical mechanism for educating the next generation of cancer clinical trialists from many different disciplines. This review outlines the overall mission, structure, and funding of the cooperative groups, beginning in 1955 when they were first established by the NCI, and describes the considerable progress against cancer achieved over the past decade.
KW - NCI Community Oncology Research Program (NCORP)
KW - NCI National Clinical Trials Network (NCTN)
KW - National Cancer Institute (NCI)
KW - cancer clinical trials
KW - cooperative groups
UR - http://www.scopus.com/inward/record.url?scp=85091382567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091382567&partnerID=8YFLogxK
U2 - 10.1002/cncr.33209
DO - 10.1002/cncr.33209
M3 - Review article
C2 - 32970346
AN - SCOPUS:85091382567
VL - 126
SP - 5022
EP - 5029
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 23
ER -